Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

11.57
-0.9300-7.44%
Post-market: 11.570.00000.00%18:38 EDT
Volume:1.33M
Turnover:15.39M
Market Cap:1.22B
PE:-7.99
High:12.25
Open:12.09
Low:11.23
Close:12.50
Loading ...

Company Profile

Company Name:
Edgewise Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
110
Office Location:
1715 38th Street,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Directors

Name
Position
Kevin Koch
President, Chief Executive Officer and Director
Peter Thompson
Co-Founder, Chairman and Director
Alan Russell
Co-Founder, Chief Scientific Officer and Director
Badreddin Edris
Co-Founder and Director
Jonathan Root
Director
Kenneth Harrison
Director
Laura Brege
Director

Shareholders

Name
Position
Kevin Koch
President, Chief Executive Officer and Director
R. Michael Carruthers
Chief Financial Officer
Alan Russell
Co-Founder, Chief Scientific Officer and Director
Behrad Derakhshan
Chief Business Officer
John Moore
General Counsel